Recent progress of nanomedicine in the treatment of Alzheimer’s disease

Frontiers in Cell and Developmental Biology

Cell and Developmental Biology

Feng Qin¹  Yanjiao Jiang²  Liqiang Hu³  Yiran Tao³ 

[1] Andrology Laboratory, West China Hospital, Sichuan University, Chengdu, China;National Chengdu Center for Safety Evaluation of Drugs, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China;College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China;Mental Health Center and West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, China;

关键词: Alzheimer’s disease;    nanomedicine;    blood-brain barrier;    nanoparticles;    bioavailability;   

DOI  :  10.3389/fcell.2023.1228679

 received in 2023-05-25, accepted in 2023-06-23,  发布年份 2023

来源: Frontiers

【 摘 要 】

Alzheimer’s disease (AD) is the most common cause of memory disruption in elderly subjects, with the prevalence continuing to rise mainly because of the aging world population. Unfortunately, no efficient therapy is currently available for the AD treatment, due to low drug potency and several challenges to delivery, including low bioavailability and the impediments of the blood-brain barrier. Recently, nanomedicine has gained considerable attention among researchers all over the world and shown promising developments in AD treatment. A wide range of nano-carriers, such as polymer nanoparticles, liposomes, solid lipid nanoparticles, dendritic nanoparticles, biomimetic nanoparticles, magnetic nanoparticles, etc., have been adapted to develop successful new treatment strategies. This review comprehensively summarizes the recent advances of different nanomedicine for their efficacy in pre-clinical studies. Finally, some insights and future research directions are proposed. This review can provide useful information to guide the future design and evaluation of nanomedicine in AD treatment.

【 授权许可】

Unknown   
Copyright © 2023 Hu, Tao, Jiang and Qin.